Larsen, J. T., Shanafelt, T. D., Leis, J. F., LaPlant, B., Call, T., Pettinger, A., . . . Ding, W. (2017). Akt inhibitor MK-2206 in combination with Bendamustine and Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia: Results from the N1087 Alliance Study. Am J Hematol.
Chicago Style citaatLarsen, Jeremy T., et al. "Akt Inhibitor MK-2206 in Combination With Bendamustine and Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia: Results From the N1087 Alliance Study." Am J Hematol 2017.
MLA citatieLarsen, Jeremy T., et al. "Akt Inhibitor MK-2206 in Combination With Bendamustine and Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia: Results From the N1087 Alliance Study." Am J Hematol 2017.
Let op: Deze citaties zijn niet altijd 100% accuraat.